Locations:
Search
Lifetime Achievement award-winner reflects on psychosocial support and caregiver readiness
Questions remain about the merits of asparaginase-based therapy
Phase 1 study found mutant calreticulin-specific monoclonal antibody brings promising results with no dose-limiting toxicities
Age alone should not rule out patients from potentially curative treatment
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Discussing research into improving CAR T-cell therapy efficacy
Combination therapy doubles the number of meaningful spleen volume responses over monotherapy
Making sense of the fast-moving treatment landscape
Combination therapy may help address underlying disease
Highlighting treatment gaps and challenges in the management of rare condition
Explaining common misconceptions about chimeric antigen receptor therapy
Advertisement
Advertisement